A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD‐(L)1 in Patients With Advanced/Metastatic Non‐Small Cell Lung Cancer Over 60% of NSCLC patients treated with immune checkpoint inhibitors (ICIs) develop acquired resistance (AR). This study demonstrates that combining tislelizumab, sitravatinib, and docetaxel achieves...

#Article in #MedComm
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...

#AcquiredResistance #Tcell #immunotherapy #PSI #TCR